Other · developed by Palisade Bio
PALI-2108 is a drug studied in ulcerative colitis, including moderate and severe forms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07845487 | Phase 2 | Ulcerative Colitis (UC) | Recruiting | PALI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Moderate Ulcerative ColitisSevere Ulcerative ColitisUlcerative Colitis (UC)
See PALI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PALI catalysts and pipeline →